Five million people worldwide are affected by<unk> . The rates below are per 100,000 persons, and the ranges reflect narrow and broad inclusion criteria, respectively. These data do not reflect any increased rates due to the COVID-19 pandemic;<unk>  is a known symptom of COVID-19 and is estimated (as of July 2020) to occur in roughly 1/3rd of patients hospitalized for COVID-19. Incidence rate Prevalence rate Population Years covered Reference 6.8-16.3 14.0-42.7 U.S. health care claims processing system 1996–2000 Raghu et al. 8.8-17.4 27.9-63.0 Olmsted County, MN 1997–2005 Fernandez Perez et al. 27.5 30.3 Males in Bernalillo County, NM 1988–1990 Coultas et al. 11.5 14.5 Females Based on these rates,<unk>  prevalence in the United States could range from more than 29,000 to almost 132,000, based on the population in 2000 that was 18 years or older. The actual numbers may be significantly higher due to misdiagnosis. Typically, patients are in their forties and fifties when diagnosed while the incidence of idiopathic<unk>  increases dramatically after the age of fifty. However, loss of pulmonary function is commonly ascribed to old age, heart disease or to more common lung diseases.
Pulmonary fibrosis
Interstitial lung disease
Pneumoconiosis
Pulmonary hyperplasia
Pulmonary toxicity
Pulmonary interstitial emphysema
Alveolar lung disease
Emphysema